Core Points - JFB Construction Holdings has secured an $18.8 million contract for the first phase of a public high school construction project in DeSoto County, Florida, which is part of a larger $100 million project [1][2] - The project will expand the existing campus by approximately 100,000 square feet over 40 acres, accommodating an additional 1,379 students [2] - The construction is set to begin in mid-October 2025, with Phase 1 expected to be completed by January 2026 [4] Company Overview - JFB Construction Holdings specializes in hospitality, commercial, industrial, and residential property development, with a strong focus on educational contracting [1][2] - The company has a robust balance sheet with over $34 million in working capital, enhancing its bonding capacity for larger projects [3] - JFB has a reputation built on client trust, with most projects obtained through referrals and repeat customers, having provided services in 36 U.S. states [6] Financial Impact - The project is anticipated to have an immediate positive impact on the company's revenue for Q4 of 2025 [4] - The value of the subsequent Phase 2 contract is projected to exceed $30 million, with construction planned to commence in June 2026 [4]

ORLANDO, Fla., Oct. 15, 2025 (GLOBE NEWSWIRE) -- Abacus Global Management, Inc. (NASDAQ: ABL) (“Abacus” or the “Company”), a leader in the alternative asset management space, today announced it will release its third quarter 2025 financial results after the market closes on Thursday, November 6, 2025. Abacus will hold a conference call to discuss the financial results at 5:00 pm Eastern Time on November 6, 2025. A live webcast of the conference call will be available on Abacus’ investor relations website at ...

DUBLIN, Ireland and BRIDGEWATER, N.J., Oct. 15, 2025 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN), a company committed to advancing the science of cardiovascular care, today announced that it will report third quarter 2025 financial results and conduct a conference call on Wednesday, October 29, 2025. The Company will issue a press release detailing its third quarter 2025 financial results in the pre-market hours, followed by a conference call with senior management at 8:00 a.m. ET. Information ...

Core Insights - Rocket Doctor AI Inc.'s subsidiary, Treatment.com Inc., has been awarded a $2 million NIH SBIR Phase II grant to develop an AI-powered, culturally sensitive family medical history tool aimed at improving early diagnosis and preventive care for diverse populations [1][7]. Funding and Project Details - The two-year grant will provide over $500,000 to Treatment for enhancing its capabilities in handling medical history data across various commercial platforms [2][7]. - The project builds on research advances from Phase 1 and aims to leverage AI to collect and apply family health history, particularly focusing on African American communities that experience higher mortality rates from certain diseases [3][4]. Collaboration and Expertise - Treatment is collaborating with Rush River Research, which brings expertise in engineering, design, and NIH grant management to the project [4][8]. - The partnership aims to create AI systems that are more accurate and human-centered by addressing historical, genetic, and cultural differences in health [5]. Goals and Impact - The initiative seeks to facilitate informed conversations about family health history, thereby enhancing preventive care, early diagnosis, and targeted screening [3][4]. - Insights gained from this project will not only benefit African American communities but will also be applicable to improve family health history for all populations [3][7]. Company Background - Rocket Doctor AI Inc. focuses on delivering AI-powered healthcare solutions designed to enhance access to quality healthcare throughout the patient journey [9][10]. - The company's Global Library of Medicine (GLM) serves as a clinically validated decision support system, supporting healthcare providers in delivering effective care [9][11].

Core Insights - Turn Therapeutics has appointed Dr. Kent E. Kester to its Board of Directors, enhancing its leadership in clinical and scientific domains at a crucial growth phase [1][3] Company Overview - Turn Therapeutics is a clinical-stage biotechnology company focused on developing next-generation therapies for dermatology, wound care, and infectious diseases [1][7] - The company has received three FDA clearances for its proprietary formulations and is advancing late-stage clinical programs in eczema and onychomycosis [7] Leadership Experience - Dr. Kester is a globally recognized infectious disease physician with over two decades of leadership experience in government, industry, and academia [2][4] - He has held senior roles, including Commander of the Walter Reed Army Institute of Research, and has led multi-center clinical programs from Phase 1 through pivotal studies [2][5] Strategic Importance - The appointment of Dr. Kester is expected to strengthen governance, sharpen strategy, and ensure a focus on patient impact and long-term value creation for Turn Therapeutics [3] - Dr. Kester's expertise in drug development and infectious disease is seen as invaluable for advancing the company's late-stage programs and approaching key regulatory milestones [3] Commitment to Public Health - Turn Therapeutics is pursuing global health initiatives, including thermostable vaccine delivery aimed at underserved areas, reflecting its commitment to public health innovation [7]

Core Points - Emmis Acquisition Corp. will separate its units into Class A ordinary shares and rights effective October 22, 2025, with new ticker symbols "EMIS" for shares and "EMISR" for rights [1] - Each unit consists of one Class A ordinary share and one right, with each right entitling the holder to receive one-tenth of a Class A ordinary share upon the completion of the initial business combination [2] - The separation is automatic, requiring no action from unit holders, and fractional shares will be rounded down or addressed according to Cayman Islands law [2] Company Overview - Emmis Acquisition Corp. is a blank check company aimed at executing mergers, amalgamations, share exchanges, asset acquisitions, or similar business combinations across various industries, focusing on industrial and business services, manufacturing, transportation, distribution, and technology sectors [4]

Core Insights - Belite Bio, Inc. has received acceptance from China's NMPA for a priority review of the New Drug Application (NDA) for Tinlarebant, aimed at treating Stargardt disease, based on interim analysis results from the Phase 3 DRAGON trial [1][2] Company Overview - Belite Bio is a clinical-stage drug development company focused on novel therapeutics for degenerative retinal diseases with significant unmet medical needs, including Stargardt disease and geographic atrophy [5] - The lead candidate, Tinlarebant, is an oral therapy designed to reduce the accumulation of vitamin A-based toxins in the eye, which are linked to retinal diseases [4][5] Clinical Trial Details - The Phase 3 DRAGON trial is a randomized, double-masked, placebo-controlled study evaluating the safety and efficacy of Tinlarebant in 104 adolescent patients with Stargardt disease across 11 jurisdictions [3] - The primary efficacy endpoint of the trial is the growth rate of atrophic lesions, with safety and tolerability also being assessed [3] Regulatory Milestones - The NMPA's acceptance of the NDA is a significant milestone for Belite Bio and the Stargardt community, highlighting the urgent need for effective therapies in this area [2] - Final topline data from the Phase 3 DRAGON trial is expected to be reported in Q4 2025, which will be submitted to the NMPA as part of the NDA [2][7]

Core Insights - Fortuna Mining Corp. has released a Preliminary Economic Assessment (PEA) for the Diamba Sud Gold Project in Senegal, indicating strong project economics with a gold price of $2,750 per ounce, resulting in an after-tax NPV5% of $563 million and an IRR of 72% [2][30][41]. Project Overview - The PEA supports the development of an open-pit mine and a conventional carbon-in-leach (CIL) processing plant, projecting an average annual production of 147,000 ounces of gold in the first three years at an All-In Sustaining Cost (AISC) of $904 per ounce [2][5][30]. - The total mineralized material mined is estimated at 17.75 million tonnes, containing 932,000 ounces of gold, with a life of mine (LOM) of 8.1 years [5][10]. Financial Metrics - The construction capital cost is estimated at approximately $283.2 million, with a payback period of ten months [3][30]. - Average operating cash costs over the LOM are projected at $1,081 per ounce, with AISC averaging $1,238 per ounce [6][30]. Exploration and Development - Ongoing exploration is expected to enhance the LOM production profile beyond a decade, with five drill rigs currently active [4][8]. - A supplementary budget of $17 million has been approved to advance early construction works and detailed engineering activities [4][40]. Environmental and Permitting - Fortuna has filed an Environmental and Social Impact Assessment (ESIA) as part of the permitting process, marking a significant milestone [38]. - The company anticipates applying for an exploitation permit before the expiration of its exploration permit in June 2026 [39]. Next Steps - The Definitive Feasibility Study (DFS) is expected to be completed by the end of the second quarter of 2026, with a construction decision anticipated shortly thereafter [41][42].

TORONTO, Oct. 15, 2025 (GLOBE NEWSWIRE) -- illumin Holdings Inc. (TSX: ILLM; OTCQB: ILLMF), a leading advertising technology company empowering marketers to see more and achieve more, today announced the appointment of Brian Garrigan as Chief Revenue Officer (CRO) ​​effective immediately. He will report to illumin’s CEO, Simon Cairns. A proven adtech leader, Brian Garrigan brings more than a decade of experience leading high-performing sales organizations and driving scalable growth across enterprise, mid-m ...

Core Viewpoint - Core AI Holdings, Inc. has launched LikeMusic.ai, an AI-driven music generation platform aimed at enhancing creative efficiency and content quality across digital media [1][3] Product Overview - LikeMusic.ai allows users to create original, production-quality music across various genres, tempos, and moods, catering to both novice and professional creators [2] - The platform supports text prompts for music generation, enabling users to specify genre, mood, tempo, and duration, with tracks typically lasting between two to four minutes [5] Technology and Integration - LikeMusic.ai integrates advanced text-to-music models and proprietary optimization techniques to improve the coherence and audio quality of AI-generated music [4] - The platform has been successfully integrated into Core Gaming's content production pipeline, leading to a 40% increase in production efficiency and reduced reliance on traditional music sourcing [6] Market Application - Early user research indicates that video producers, advertisers, and independent game developers are the most active users of LikeMusic.ai, which is optimized for web use to align with professional workflows [7] - The platform's capabilities are positioned to support high-volume content production environments through API integration and batch generation [5] Company Background - Core AI Holdings, Inc. is an international mobile games developer and publisher, having developed over 2,100 games and achieved over 780 million downloads globally [8]